• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

强化治疗后,异基因造血干细胞移植受者的重症监护病房存活率得到提高。

Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning.

机构信息

Department of Haematology, University College London Hospitals NHS Foundation Trust and UCL Medical School, London, UK.

出版信息

Br J Haematol. 2013 May;161(4):578-86. doi: 10.1111/bjh.12294. Epub 2013 Mar 18.

DOI:10.1111/bjh.12294
PMID:23496350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4296346/
Abstract

The use of allogeneic haematopoietic stem cell transplantation (Allo-HSCT) is a standard treatment option for many patients with haematological malignancies. Historically, patients requiring intensive care unit (ICU) admission for transplant-related toxicities have fared extremely poorly, with high ICU mortality rates. Little is known about the impact of reduced intensity Allo-HSCT conditioning regimens in older patients on the ICU and subsequent long-term outcomes. A retrospective analysis of data collected from 164 consecutive Allo-HSCT recipients admitted to ICU for a total of 213 admissions, at a single centre over an 11·5-year study period was performed. Follow-up was recorded until 31 March 2011. Autologous HSCT recipients were excluded. In this study we report favourable ICU survival following Allo-HSCT and, for the first time, demonstrate significantly better survival for patients who underwent Allo-HSCT with reduced intensity conditioning compared to those treated with myeloablative conditioning regimens. In addition, we identified the need for ventilation (invasive or non-invasive) as an independently significant adverse factor affecting short-term ICU outcome. For patients surviving ICU admission, subsequent long-term overall survival was excellent; 61% and 51% at 1 and 5 years, respectively. Reduced intensity Allo-HSCT patients admitted to ICU with critical illness have improved survival compared to myeloablative Allo-HSCT recipients.

摘要

同种异体造血干细胞移植(Allo-HSCT)的应用是许多血液恶性肿瘤患者的标准治疗选择。历史上,因移植相关毒性而需要入住重症监护病房(ICU)的患者预后极差,ICU 死亡率极高。对于接受减强度 Allo-HSCT 预处理方案的老年患者在 ICU 中的影响以及随后的长期预后,知之甚少。对在单一中心 11.5 年的研究期间连续收治的 164 例因移植相关毒性而总共入住 ICU 213 次的 Allo-HSCT 受者的数据进行了回顾性分析。随访记录至 2011 年 3 月 31 日。排除了自体 HSCT 受者。在这项研究中,我们报告了 Allo-HSCT 后 ICU 存活率良好,并且首次证明与接受清髓性预处理方案相比,接受减强度预处理方案的患者具有更好的生存结果。此外,我们发现需要通气(有创或无创)是影响短期 ICU 结果的独立不良因素。对于存活 ICU 入住的患者,随后的长期总生存率非常好;分别为 1 年和 5 年时的 61%和 51%。与接受清髓性 Allo-HSCT 的患者相比,因危重病而入住 ICU 的接受减强度 Allo-HSCT 的患者的存活率有所提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c089/4296346/06ea0ae0a1ab/bjh0161-0578-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c089/4296346/06ea0ae0a1ab/bjh0161-0578-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c089/4296346/06ea0ae0a1ab/bjh0161-0578-f1.jpg

相似文献

1
Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning.强化治疗后,异基因造血干细胞移植受者的重症监护病房存活率得到提高。
Br J Haematol. 2013 May;161(4):578-86. doi: 10.1111/bjh.12294. Epub 2013 Mar 18.
2
Prognostic factors for patients with hematologic malignancies admitted to the intensive care unit: is allogeneic transplantation still a risk factor?血液恶性肿瘤患者入住重症监护病房的预后因素:异基因移植仍然是危险因素吗?
Ann Hematol. 2023 Apr;102(4):907-916. doi: 10.1007/s00277-023-05118-4. Epub 2023 Feb 9.
3
Outcomes and Long-Term Survival of Adolescent and Young Adult Patients Admitted to the Intensive Care Unit Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience of 152 Patients.异基因造血干细胞移植后入住重症监护病房的青少年和年轻成人患者的结局和长期生存:单中心 152 例患者经验。
Hematol Oncol Stem Cell Ther. 2024 Mar 22;17(2):110-119. doi: 10.56875/2589-0646.1114.
4
Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit.减低强度预处理方案后异基因造血干细胞移植:入住重症监护病房患者的结局
J Crit Care. 2015 Oct;30(5):1107-13. doi: 10.1016/j.jcrc.2015.06.020. Epub 2015 Jun 24.
5
Clinical outcomes in allogeneic haematopoietic stem cell transplantation: A comparison between young and elderly patients. Observational study.异基因造血干细胞移植的临床结局:年轻患者与老年患者的比较。观察性研究。
Eur J Cancer Care (Engl). 2019 Sep;28(5):e13122. doi: 10.1111/ecc.13122. Epub 2019 Jun 30.
6
Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients.强化治疗病房收治的异基因造血干细胞移植受者的短期和长期预后改善:942 例患者的回顾性纵向分析。
Intensive Care Med. 2018 Sep;44(9):1483-1492. doi: 10.1007/s00134-018-5347-x. Epub 2018 Aug 23.
7
Prognosis of Allogeneic Haematopoietic Stem Cell Recipients Admitted to the Intensive Care Unit: A Retrospective, Single-Centre Study.入住重症监护病房的异基因造血干细胞接受者的预后:一项回顾性单中心研究。
Acta Haematol. 2016;135(2):72-8. doi: 10.1159/000440937. Epub 2015 Oct 20.
8
Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports.危重症异基因造血干细胞移植受者的结局:对器官功能衰竭支持指征的重新评估
J Clin Oncol. 2006 Feb 1;24(4):643-9. doi: 10.1200/JCO.2005.03.9073. Epub 2005 Dec 27.
9
Admission of hematopoietic cell transplantation patients to the intensive care unit at the Pontificia Universidad Católica de Chile Hospital.智利天主教大学医院造血细胞移植患者入住重症监护病房情况。
Biol Blood Marrow Transplant. 2015 Jan;21(1):176-9. doi: 10.1016/j.bbmt.2014.08.009. Epub 2014 Aug 17.
10
Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data.入住重症监护病房的血液系统恶性肿瘤患者的预后。异基因造血干细胞移植数据的比较性综述。
Br J Haematol. 2007 Feb;136(3):448-50. doi: 10.1111/j.1365-2141.2006.06440.x. Epub 2006 Dec 8.

引用本文的文献

1
Temporal trends in critical care utilization and outcomes in allogeneic hematopoietic stem cell transplant recipients.异基因造血干细胞移植受者的重症监护利用和结局的时间趋势。
Ann Hematol. 2024 Mar;103(3):957-967. doi: 10.1007/s00277-023-05612-9. Epub 2024 Jan 3.
2
Prognostic Factors and Intensive Care Outcome in Post-Transplant Phase of Hematopoietic Stem Cell Transplantation: Intensive Care Outcome in Hematopoietic Stem Cell Transplantation.造血干细胞移植后移植期的预后因素与重症监护结局:造血干细胞移植的重症监护结局
Indian J Hematol Blood Transfus. 2023 Apr;39(2):167-172. doi: 10.1007/s12288-022-01575-5. Epub 2022 Oct 11.
3

本文引用的文献

1
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.供者淋巴细胞输注可调节混合嵌合体中的复发风险,并可在霍奇金淋巴瘤患者接受 T 细胞耗竭的异基因移植后复发时进行持久挽救。
J Clin Oncol. 2011 Mar 10;29(8):971-8. doi: 10.1200/JCO.2010.32.1711. Epub 2011 Jan 31.
2
Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT: a single-centre experience.异基因骨髓或外周造血干细胞移植治疗危重症患者的结果:单中心经验。
Bone Marrow Transplant. 2011 Sep;46(9):1186-91. doi: 10.1038/bmt.2010.255. Epub 2010 Nov 1.
3
Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation.
移植前个体合并症对异基因造血干细胞移植后入住重症监护病房的风险及生存结局的影响。
Bone Marrow Transplant. 2023 Mar;58(3):311-316. doi: 10.1038/s41409-022-01897-y. Epub 2022 Dec 12.
4
Outcome of allogeneic hematopoietic stem cell transplant recipients admitted to the intensive care unit with a focus on haploidentical graft and sequential conditioning regimen: results of a retrospective study.入住重症监护病房的异基因造血干细胞移植受者的结局,重点关注单倍体相合移植物和序贯预处理方案:一项回顾性研究结果
Ann Hematol. 2021 Nov;100(11):2787-2797. doi: 10.1007/s00277-021-04640-7. Epub 2021 Sep 3.
5
[Bone marrow transplantation patients in the intensive care unit].重症监护病房中的骨髓移植患者
Med Klin Intensivmed Notfmed. 2021 Mar;116(2):111-120. doi: 10.1007/s00063-021-00782-8. Epub 2021 Feb 9.
6
Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician.免疫治疗和/或干细胞移植后危重症患者的临床处理:值班医生指南
J Clin Med. 2019 Jun 20;8(6):884. doi: 10.3390/jcm8060884.
7
Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data.过去几十年中重症癌症患者短期预后的变化:系统评价与个体数据荟萃分析的结果。
Intensive Care Med. 2019 Jul;45(7):977-987. doi: 10.1007/s00134-019-05653-7. Epub 2019 May 29.
8
Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation.造血干细胞移植后在重症监护病房接受治疗的患者的长期预后
Int J Hematol. 2018 Dec;108(6):622-629. doi: 10.1007/s12185-018-2536-x. Epub 2018 Sep 20.
9
Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients.强化治疗病房收治的异基因造血干细胞移植受者的短期和长期预后改善:942 例患者的回顾性纵向分析。
Intensive Care Med. 2018 Sep;44(9):1483-1492. doi: 10.1007/s00134-018-5347-x. Epub 2018 Aug 23.
10
Prognostic factors in critically ill patients with hematological malignancy admitted to the general intensive care unit: a single-center experience in Japan.入住综合重症监护病房的血液系统恶性肿瘤重症患者的预后因素:日本单中心经验
J Anesth. 2017 Oct;31(5):736-743. doi: 10.1007/s00540-017-2390-7. Epub 2017 Aug 1.
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.
T 细胞 depleted 降低强度移植后输注供者白细胞以促进移植物抗淋巴瘤活性可使复发性滤泡性淋巴瘤患者获得极好的长期生存。
J Clin Oncol. 2010 Aug 10;28(23):3695-700. doi: 10.1200/JCO.2009.26.9100. Epub 2010 Jul 6.
4
Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission.危重病区重新配置和跟踪-触发外展团队干预对需要重症监护入院的血液学患者结局的影响。
Ann Hematol. 2010 May;89(5):505-12. doi: 10.1007/s00277-009-0853-0. Epub 2009 Oct 30.
5
Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT.下呼吸道呼吸道病毒感染会增加异基因造血干细胞移植后低强度治疗患者侵袭性曲霉病的风险。
Bone Marrow Transplant. 2009 Dec;44(11):749-56. doi: 10.1038/bmt.2009.78. Epub 2009 Apr 27.
6
Intensive care outcomes in bone marrow transplant recipients: a population-based cohort analysis.骨髓移植受者的重症监护结局:一项基于人群的队列分析。
Crit Care. 2008;12(3):R77. doi: 10.1186/cc6923. Epub 2008 Jun 11.
7
Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.急性髓系白血病的全强度和降低强度异基因干细胞移植
Bone Marrow Transplant. 2008 Mar;41(5):415-23. doi: 10.1038/sj.bmt.1705975. Epub 2008 Jan 21.
8
Intensive insulin therapy and pentastarch resuscitation in severe sepsis.严重脓毒症的强化胰岛素治疗与羟乙基淀粉复苏
N Engl J Med. 2008 Jan 10;358(2):125-39. doi: 10.1056/NEJMoa070716.
9
Predictors of short and long-term outcome in patients with hematological disorders admitted to the intensive care unit for a life-threatening complication.因危及生命的并发症入住重症监护病房的血液系统疾病患者短期和长期预后的预测因素。
Support Care Cancer. 2007 Dec;15(12):1393-8. doi: 10.1007/s00520-007-0268-1. Epub 2007 May 22.
10
Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data.入住重症监护病房的血液系统恶性肿瘤患者的预后。异基因造血干细胞移植数据的比较性综述。
Br J Haematol. 2007 Feb;136(3):448-50. doi: 10.1111/j.1365-2141.2006.06440.x. Epub 2006 Dec 8.